An exponential growth of computational phantom research in radiation protection, imaging, and radiotherapy: a review of the fifty-year history
XG Xu - Physics in Medicine & Biology, 2014 - iopscience.iop.org
Radiation dose calculation using models of the human anatomy has been a subject of great
interest to radiation protection, medical imaging, and radiotherapy. However, early pioneers …
interest to radiation protection, medical imaging, and radiotherapy. However, early pioneers …
British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice
N Reed, J Balega, T Barwick, L Buckley… - European Journal of …, 2021 - Elsevier
Cervix cancer in many countries is declining and screening programmes and immunisation
will reduce the incidence in the next few decades. This guideline attempts to cover …
will reduce the incidence in the next few decades. This guideline attempts to cover …
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant …
J Kurth, BJ Krause, SM Schwarzenböck… - European journal of …, 2020 - Springer
Purpose Besides PSMA, prostate cancer cells also express gastrin-releasing peptide
receptor (GRPr) which is therefore a promising target for theranostic approaches. The high …
receptor (GRPr) which is therefore a promising target for theranostic approaches. The high …
177Lu-labeled albumin-binder–conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio
The use of an albumin binder has been shown to improve tumor uptake of prostate-specific
membrane antigen (PSMA)–targeting radiotherapeutic agents. The aim of this study was to …
membrane antigen (PSMA)–targeting radiotherapeutic agents. The aim of this study was to …
[HTML][HTML] Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects
R Danieli, A Milano, S Gallo, I Veronese… - Journal of Personalized …, 2022 - mdpi.com
Targeted radiation therapy (TRT) is a strategy increasingly adopted for the treatment of
different types of cancer. The urge for optimization, as stated by the European Council …
different types of cancer. The urge for optimization, as stated by the European Council …
An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge
In this work, we present details and initial results from a 177 Lu dosimetry challenge that has
been designed to collect data from the global nuclear medicine community aiming at …
been designed to collect data from the global nuclear medicine community aiming at …
Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
CH Pfob, S Ziegler, FP Graner, M Köhner… - European journal of …, 2016 - Springer
Purpose Positron emission tomography (PET) agents targeting the prostate-specific
membrane antigen (PSMA) are currently under broad clinical and scientific investigation. 68 …
membrane antigen (PSMA) are currently under broad clinical and scientific investigation. 68 …
VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4
SD Kost, YK Dewaraja, RG Abramson… - Cancer Biotherapy and …, 2015 - liebertpub.com
We have developed the Voxel-Based Internal Dosimetry Application (VIDA) to provide
patient-specific dosimetry in targeted radionuclide therapy performing Monte Carlo …
patient-specific dosimetry in targeted radionuclide therapy performing Monte Carlo …
A feasibility study of the therapeutic application of a mixture of 67/64Cu radioisotopes produced by cyclotrons with proton irradiation
L De Nardo, G Pupillo, L Mou, J Esposito… - Medical …, 2022 - Wiley Online Library
Abstract Purpose 64Cu and 67Cu radioisotopes have nuclear characteristics suitable for
nuclear medicine applications. The production of 64Cu is already well established …
nuclear medicine applications. The production of 64Cu is already well established …
[HTML][HTML] 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti …
A Gosewisch, H Ilhan, S Tattenberg, A Mairani… - EJNMMI research, 2019 - Springer
Background The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand
therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM …
therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM …